|Bid||72.57 x 700|
|Ask||72.58 x 500|
|Day's Range||71.83 - 72.62|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.66|
|Dividend & Yield||2.08 (2.84%)|
|1y Target Est||N/A|
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.